Zhe-Yu Hu

ORCID: 0000-0003-0932-9745
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Radiomics and Machine Learning in Medical Imaging
  • Breast Cancer Treatment Studies
  • Cancer Cells and Metastasis
  • AI in cancer detection
  • COVID-19 diagnosis using AI
  • Genetic factors in colorectal cancer
  • Cancer-related molecular mechanisms research
  • Lung Cancer Diagnosis and Treatment
  • Cancer, Hypoxia, and Metabolism
  • HER2/EGFR in Cancer Research
  • Nanoplatforms for cancer theranostics
  • Cancer Treatment and Pharmacology
  • RNA modifications and cancer
  • Cancer-related Molecular Pathways
  • Brain Metastases and Treatment
  • Hedgehog Signaling Pathway Studies
  • MicroRNA in disease regulation
  • Energy and Environment Impacts
  • Long-Term Effects of COVID-19
  • Multiple and Secondary Primary Cancers
  • Nausea and vomiting management
  • Thyroid Cancer Diagnosis and Treatment
  • Lung Cancer Treatments and Mutations

Hunan Cancer Hospital
2018-2024

Central South University
2014-2024

Xiangtan University
2024

Sun Yat-sen University
2012-2023

University College London
2021

The First Hospital of Changsha
2017

Emory University
2016-2017

Third Xiangya Hospital
2016

Xiangya Hospital Central South University
2013-2015

Ministry of Education of the People's Republic of China
2015

Abstract Background Accurate and robust pathological image analysis for colorectal cancer (CRC) diagnosis is time-consuming knowledge-intensive, but essential CRC patients’ treatment. The current heavy workload of pathologists in clinics/hospitals may easily lead to unconscious misdiagnosis based on daily analyses. Methods Based a state-of-the-art transfer-learned deep convolutional neural network artificial intelligence (AI), we proposed novel patch aggregation strategy clinic using weakly...

10.1186/s12916-021-01942-5 article EN cc-by BMC Medicine 2021-03-23

To develop a fully automated AI system to quantitatively assess the disease severity and progression of COVID-19 using thick-section chest CT images.In this retrospective study, an was developed automatically segment quantify COVID-19-infected lung regions on images. Five hundred thirty-one scans from 204 patients were collected one appointed hospital. The segmented abnormalities compared with manual segmentation two experienced radiologists Dice coefficient randomly selected subset (30...

10.1007/s00330-020-07042-x article EN other-oa European Radiology 2020-07-18

PurposeIn cancer patients, tumor gene mutations contribute to drug resistance and treatment failure. In patients with metastatic breast (MBC), these increase after multiline treatment, thereby decreasing efficiency. The aim of this study was evaluate mutation patterns in MBC predict disease progression.MethodA total 68 who had received were recruited. Circulating DNA (ctDNA) evaluated compared among hormone receptor (HR)/human epidermal growth factor 2 (HER2) subgroups.ResultsThe baseline...

10.1016/j.ebiom.2018.05.015 article EN cc-by-nc-nd EBioMedicine 2018-05-26

Bronchoscopy inspection, as a follow-up procedure next to the radiological imaging, plays key role in diagnosis and treatment design for lung disease patients. When performing bronchoscopy, doctors have make decision immediately whether perform biopsy. Because biopsies may cause uncontrollable life-threatening bleeding of tissue, thus need be selective with biopsies. In this paper, help more on provide second opinion diagnosis, we propose computer-aided (CAD) system diseases, including...

10.1109/jtehm.2018.2865787 article EN cc-by-nc-nd IEEE Journal of Translational Engineering in Health and Medicine 2018-01-01

// Luqing Zhao 1,2,3,4 , Min Tang Zheyu Hu Bin Yan Weiwei Pi 5,6 Zhi Li 5 Jing Zhang 6 Liqin 8 Wuzhong Jiang Guo 7 Yuanzheng Qiu Fang 9 Feng Liu Jingchen Lu 1,6 Xue Chen Lanbo Xiao Zhijie Xu Yongguang Tao Lifang Yang Ann M. Bode 10 Zigang Dong Jian Zhou 11 Jia Fan Lunquan Sun 4,5 and Ya Cao 1 Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, China 2 Key Laboratory Carcinogenesis Invasion, Ministry Education, 3 Carcinogenesis, Health, 4 Molecular...

10.18632/oncotarget.4138 article EN Oncotarget 2015-05-14

Circulating tumor DNA (ctDNA) has good clinical guiding value for metastatic breast cancer (MBC) patients. This study aimed to apply a novel genetic analysis approach therapeutic prediction based on ctDNA alterations.This nonrandomized, multicenter recruited 223 MBC patients (NCT05079074). Plasma samples were collected target-capture deep sequencing of at baseline, after the 2nd cycle treatment, and when progressive disease (PD) was evaluated. Samples categorized into four levels according...

10.1016/j.breast.2022.07.010 article EN The Breast 2022-07-19

Case report A 55-year-old male patient developed a mass in the left inguinal area with lower limb swelling and first visited local hospital 3 months earlier because of unrelieved pain. An MRI scan suggested suprapubic branch acetabular bone destruction, abnormal soft tissue signals within iliopsoas muscle anterior edge iliac bone, enlarged lymph nodes fossa region. The subsequently underwent pelvic lesion open biopsy node resection biopsy. According to pathological reports, was considered be...

10.3389/fimmu.2024.1337400 article EN cc-by Frontiers in Immunology 2024-05-28

Objectives We aimed to determine the most efficient quantitative parameters establish a contrast‐enhanced ultrasound (US) assessment system for distinguishing between benign and malignant thyroid nodules. Methods A total of 167 patients with solitary nodules had diagnosis confirmed by surgery or fine‐needle aspiration. Quantitative US indicators (time peak, time from peak one‐half, ascend slope, descend intensity, area under curve [AUC]) were gathered in nodule perinodule areas. Univariate...

10.1002/jum.14347 article EN Journal of Ultrasound in Medicine 2017-09-07

Abstract Background Human epidermal growth factor receptor 2 (HER2) targeted therapy combined with endocrine has been recommended as an alternative treatment strategy for patients hormone (HR)-positive, HER2-positive metastatic breast cancer (MBC). This study aimed to evaluate the role of pyrotinib, oral pan-HER irreversible tyrosine kinase inhibitor, in combination letrozole HR-positive, MBC. Methods In this multi-center, phase II trial, HR-positive and MBC who were not previously treated...

10.1186/s12916-023-02943-2 article EN cc-by BMC Medicine 2023-06-26

Aims Paroxysmal atrial fibrillation ( PAF ) commonly recurs after radiofrequency catheter ablation RFCA ). This study aimed to assess left appendage LAA volume and function by transesophageal echocardiography TEE explore its value in predicting recurrence . Methods Eighty patients with were recruited. The LA measured transthoracic TTE before ablation. Patients followed up for 12 months , was recorded. Odds ratios of candidate risk indicators determined logistic regression analysis....

10.1111/echo.13856 article EN Echocardiography 2018-03-06

Aim: Early detection and correct diagnosis of lung cancer are the most important steps in improving patient outcome. This study aims to assess which deep learning models perform best diagnosis. Methods: Non-small cell carcinoma small biopsy specimens were consecutively obtained stained. The specimen slides diagnosed by two experienced pathologists (over 20 years). Several trained discriminate non-cancer biopsies. Result: Deep give reasonable AUC from 0.8810 0.9119. Conclusion: analysis could...

10.48550/arxiv.1803.05471 preprint EN other-oa arXiv (Cornell University) 2018-01-01

In triple-negative breast cancer (TNBC), PDL1/PD1-directed immunotherapy is effective in less than 20% of patients. our preliminary study, we have found CSPG4 to be highly expressed together with PDL1 TNBCs, particularly those harboring TP53 aberrations. However, the clinical implications co-expressed and TNBCs remain elusive.A total 85 advanced TNBC patients treated Hunan Cancer Hospital between January 2017 August 2019 were recruited. The expressions tissues investigated using...

10.3389/fonc.2022.804466 article EN cc-by Frontiers in Oncology 2022-02-24

Among breast cancer (BC) patients, near 40% are post-menopause, and 70%–80% hormone receptor (HR)-positive. About 30%–40% BC patients who diagnosed as invasive carcinoma HR-positive would eventually develop metastatic cancers. In 2016, FALCON trial proves Fulvestrant an effective first-line endocrine therapy for post-menopause advanced (ABC) patients. But even after published, is rarely used in real world ABC China. this study, 136 users were enrolled from 2015. To investigate the clinical...

10.1186/s12967-018-1734-x article EN cc-by Journal of Translational Medicine 2019-01-15

The overall survival of breast cancer (BC) patients increased significantly for decades; however, their long-term was seriously impaired by subsequent malignancies. This study aimed to investigate the risk factors lung / bronchus primary malignancies among BC survivors. A total 535,941 female survivors diagnosed were identified using SEER*Stat database in 1973 2014. Among them, 9398 had lung/bronchus Clinico-pathological evaluated development cancer. main measures incidence and primaries....

10.1097/md.0000000000012603 article EN cc-by-nc Medicine 2018-09-01

Background: The survival status of patients with breast cancer and brain metastasis (BCBM) receiving current treatments is poor. Method: We designed a real-world study to investigate using patients’ clinical genetic aberrations forecast the prognoses BCBM patients. recruited 146 analyzed their features evaluate overall (OS). For testing, 30 165 non-brain-metastatic (BM) metastatic (MBC) from Hunan Cancer Hospital, 86 1416 non-BM MBC Geneplus database who received circulating tumor DNA were...

10.1177/1758835920915305 article EN cc-by-nc Therapeutic Advances in Medical Oncology 2020-01-01

There is ongoing debate about surgery of primary site in nasopharyngeal carcinoma patients. 3919 patients with identified the SEER registry between 2004 and 2013. The benefit nasopharynx tumor on overall cancer-specific survival was assessed by risk-adjusted multivariate Cox proportional hazard regression propensity score matching modeling. Surgery marginally associated better (hazard ratio (HR) = 0.816, 95% CI 0.656–1.015, p 0.07) (HR 0.749, 0.552–1.018, 0.06) model. Among 398 cases who...

10.1186/s12967-017-1204-x article EN cc-by Journal of Translational Medicine 2017-05-30

Clinically diagnosed partial epilepsy is hard to be functionally by regular electroencephalograph (EEG) and conventional magnetic resonance imaging (MRI). By collecting transient brain regional signals, blood oxygenation level-dependent (BOLD) function MRI (BOLD-fMRI) can provide change information with high accuracy. using resting state BOLD-fMRI technique, we aim investigate the changes of in patients.BOLD-fMRI scanning was performed 70 healthy people. data analyzed Regional Homogeneity...

10.18632/oncotarget.20575 article EN Oncotarget 2017-08-28

PURPOSE: Accumulation of PIK3CA, ESR1, and GATA3 mutations results in resistance to endocrine therapy breast cancer patients; however, the response these genes chemotherapy is unclear. Therefore, we sought evaluate genetic circulating tumor DNA (ctDNA) metastatic patients. METHODS: The mutation frequency 1021 was examined prior ctDNA 44 estrogen receptor–positive These were evaluated again a subset patients (n=24) following chemotherapy. Mutation defined as percentage found compared total...

10.1016/j.tranon.2019.02.014 article EN cc-by-nc-nd Translational Oncology 2019-03-17

Lymphoma is one of the most common types hematological malignancies and proteins from Bcl-2 family are highly expressed in human lymphomas. Apogossypolone (ApoG2), potent gossypol derivative, has been classified as a novel small-molecule inhibitor antiapoptotic proteins. Here, we assessed in-vitro cytotoxicity ApoG2 on U937 lymphoma cells, explored underlying intracellular molecular mechanisms ApoG2. Using WST-8 assay, found that inhibited growth cells dose-dependent time-dependent manner,...

10.1097/cad.0b013e32831087e8 article EN Anti-Cancer Drugs 2008-11-01
Coming Soon ...